SNDX

AI Memo

Syndax

As of 2026-08-04/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Axatilimab Phase 2 topline data • 2026-11-02

Expected move: +26%

Biggest risk

The thesis remains exposed to binary clinical outcomes, durability of commercial uptake, and execution across multiple launches and trials. The upcoming earnings event could disappoint if results, guidance, or commentary fail to validate expectations.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Syndax combines commercial revenue from Revuforj and Niktimvo with potential frontline AML expansion and axatilimab readouts. Q1 revenue and uptake data support a constructive operating foundation [#SEC-8K-2026-04-30].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-04

Base target

$24

p=50%

Bull target

$35

p=25%

Bear target

$12

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-quarter results and business update
Commercial scaling and frontline AML expansion
Syndax combines commercial revenue from Revuforj and Niktimvo with potential frontline AML expansion and axatilimab readouts.

BearKey bullets

Binary or delayed axatilimab and frontline AML clinical milestones.
Commercial uptake, treatment duration, payer coverage, or prescriber expansion may fall short of expectations.
Recent Form 4 activity includes open-market sales by the CEO and Head of R&D/CMO; this is an ownership signal, not evidence about operating performance [#SEC-FORM4-2026-07-09].

WatchKey bullets

Axatilimab Phase 2 topline data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $24 (p=50%)

Bull/Bear spread: +83% / -37%

Vs latest close: Bull +83% · Base +26% · Bear -37%

Scenario probabilities

Bull Target: $35 (p=25%)Base Target: $24 (p=50%)Bear Target: $12 (p=25%)

Commentary

The deterministic prior is positive, but the evidence supports cautious monitoring rather than high-conviction momentum. Recent-news and social coverage data are unavailable, and the earnings release has not yet been provided in the packet. Low coverage, incomplete analyst-revision data, and a loose peer set reduce confidence.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-quarter results and business update
Commercial scaling and frontline AML expansion

Scenarios

Bull Target (Scenario probability)

$35 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$12 / p=25% prob

Price $19 as of 2026-08-04

Nearest Scenario: Base (∆ 26%)

Targets vs latest close: Bull +83% · Base +26% · Bear -37%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-02
Axatilimab Phase 2 topline data
The company expected topline data in the fourth quarter of 2026 from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis and newly diagnosed chronic graft-versus-host disease [#SEC-8K-2026-04-30].
Prob 40.00% • Move 20.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Second-quarter results and business update
2026-08-04
Syndax scheduled its second-quarter 2026 results and business update for August 4, 2026 [#PR-EARNINGS-2026-07-28]. The packet does not provide reported results, consensus comparisons, or guidance changes, so this is an event-risk setup rather than confirmed upside.
Prob 100% • Move 8% • Priced-in 65%

Long-term Catalysts

Months to a year

Commercial scaling and frontline AML expansion
2027-08-04
First-quarter materials reported $48.9 million of Revuforj revenue, $55.1 million of Niktimvo net revenue, strong uptake, and global site initiation and enrollment in pivotal frontline AML trials [#SEC-8K-2026-04-30]. Sustained commercial execution and positive development data could support multi-year franchise expansion.
Prob 45% • Move 30% • Priced-in 30%

Risks

Binary or delayed axatilimab and frontline AML clinical milestones.
Commercial uptake, treatment duration, payer coverage, or prescriber expansion may fall short of expectations.
Recent Form 4 activity includes open-market sales by the CEO and Head of R&D/CMO; this is an ownership signal, not evidence about operating performance [#SEC-FORM4-2026-07-09].
The packet lacks current-quarter reported results, consensus surprise data, guidance revisions, and analyst estimate or target changes.

Peers

Symbol	Summary
CLDX	Celldex is a similar-cap biotech with high clinical optionality, but it lacks Syndax's commercial dual-product revenue base; it is primarily a pipeline-risk reference.
NRIX	Nurix is a closer hematology/oncology development-stage comparison on size and scientific optionality, while Syndax has stronger current revenue visibility if its products continue scaling.
ANIP	ANI Pharmaceuticals provides a same-cap commercial-execution reference, but it is not a direct mechanism or indication peer and should receive limited valuation weight.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

AI Stock Memo: SNDX - Syndax - RankAlpha